男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影
     
 
Home> News
China and Cuba co-develop new anti-cancer vaccine
(chinadaily.com.cn)
Updated: 2012-03-29
 

Jointly developed by China and Cuba, a new kind of vaccine used to treat non-small-cell lung cancer (NSCLC) has obtained the approval of China's State Food and Drug Administration. It is about to conduct clinical tests at the Chinese Academy of Medical Sciences (CAMS).

The news was released at the China-Cuba Biopharmaceutical Achievement Analysis and Prospect Conference, held by the Biotech Pharmaceuticals Co Ltd.

Dr. Agustín Lage Dávila is the director of the Center of Molecular Immunology and is a renowned biotechnologist in Cuba. He said, "After diagnosis, the development of the tumor will usually disappear and recur with therapy progress."

Dr. Lage said Cimavax, the new vaccine that was jointly developed by Cuba and Biotech, is a conjugated vaccine that recombines the epidermal growth factor (EGF). As a therapeutic vaccine, it directs the EGF required by tumor expansion and prevents the further proliferation of tumor tissues. It thereby keeps the tumor at a stable level and transforms the cancer into a chronic disease, which greatly extends the survival time of the patient.

The clinical trial of this therapeutic vaccine has been conducted in Cuba with local drug registration. Meanwhile, many countries and regions in Europe and Asia have launched the registration trials of the vaccine and have gained positive preliminary results. At present, the vaccine is being converted into product for China.

The Cancer Hospital of CAMS is the partner of the Phase I clinical trial of the project. Vice-president professor, Shi Yuankai, confirmed that the new vaccine will first enter the Phase I clinical trial in the hospital starting in March. Dr. Lage predicted that after two years of clinical trials, the new anticancer vaccine will be put into the market.

As the largest project of the China-Cuba biological cooperation, Biotech has acquired spectacular results in the field of biopharmaceutical anticancer. During its development in the past decade, Biotech has made remarkable achievements in tumor research and treatment and created the first domestic antibody humanization technology platform at a world leading level.

The company has also designed and constructed China's first full-automatic and large-scale mammalian cell culture production line, and researched and developed Nimotuzomab - the first humanized monoclonal antibody of gene recombination for malignant tumor treatment.

Edited by Chen Zhilin and Rakhee M

 

Zhang Hui

Zhang Hui, Board Chairman and Chief Executive Officer of Beijing Innofidei.

 

Yu Zhenhua

Yu Zhenhua, Board Chairman of Beijing Prudent Energy Inc.

 

Deng Zhonghan

Deng Zhonghan, Board Chairman of Vimicro.

 
 

Zhongguancun Science Park

主站蜘蛛池模板: 远安县| 阳信县| 鄢陵县| 扎鲁特旗| 孟州市| 鄢陵县| 拉萨市| 曲麻莱县| 汝阳县| 萨嘎县| 布尔津县| 繁峙县| 庆安县| 繁昌县| 昌平区| 沂南县| 盐亭县| 普兰县| 芦溪县| 武清区| 平泉县| 大安市| 福清市| 石屏县| 德江县| 陆良县| 汶上县| 社旗县| 老河口市| 石首市| 诸暨市| 永靖县| 邮箱| 和平县| 北票市| 华池县| 汕尾市| 清远市| 安岳县| 佛坪县| 长乐市| 舒城县| 阿拉善盟| 南部县| 余姚市| 庆安县| 东乡族自治县| 金山区| 宁陕县| 绥滨县| 邳州市| 茶陵县| 台湾省| 江山市| 濮阳市| 江油市| 泸溪县| 聂拉木县| 化德县| 新乐市| 堆龙德庆县| 三原县| 五大连池市| 土默特左旗| 鹿泉市| 屏南县| 濉溪县| 三河市| 青阳县| 崇左市| 腾冲县| 武功县| 富锦市| 新沂市| 满洲里市| 邵武市| 云浮市| 灵石县| 东乡族自治县| 万源市| 顺义区| 靖宇县|